Singapore, Feb. 24 -- Hangzhou Sciwind Biosciences has announced a strategic commercialisation collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new-generation cAMP-biased GLP-1 receptor agonist.

Under the agreement, Pfizer will obtain exclusive commercialisation rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China.

Sciwind Biosciences will remain the Marketing Authorisation Holder and will be responsible for research and development, registration, manufacturing, and supply of the product.

Under the terms of the agreement, Sciwind Biosciences is eligible to receive up to $495 million in upfront, regulatory and sales milesto...